{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Acute Respiratory Distress Syndrome",
            "NStudiesAvail": 430108,
            "NStudiesFound": 56,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 56,
            "FieldList": [
                  "OutcomeClassDenomCountGroupId",
                  "OutcomeClassDenomCountValue",
                  "OutcomeClassDenomUnits",
                  "OutcomeClassTitle",
                  "OutcomeDenomCountGroupId",
                  "OutcomeDenomCountValue",
                  "OutcomeDenomUnits",
                  "OutcomeGroupDescription",
                  "OutcomeGroupId",
                  "OutcomeGroupTitle",
                  "OutcomeMeasureAnticipatedPostingDate",
                  "OutcomeMeasureCalculatePct",
                  "OutcomeMeasureDenomUnitsSelected",
                  "OutcomeMeasureDescription",
                  "OutcomeMeasureDispersionType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT02804945"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002"
                        ],
                        "OutcomeDenomCountValue": [
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3",
                              "3"
                        ],
                        "OutcomeDenomUnits": [
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants"
                        ],
                        "OutcomeGroupDescription": [
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts."
                        ],
                        "OutcomeGroupId": [
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002"
                        ],
                        "OutcomeGroupTitle": [
                              "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
                              "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW"
                        ],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [
                              "Any of the following occurring within 6 h of mesenchymal stem-cell infusion:\n\nAddition of a third vasopressor or an increase in vasopressor dose greater than or equal to the following:\nNorepinephrine: 10 \u03bcg per min\nPhenylephrine: 100 \u03bcg per min\nDopamine: 10 \u03bcg/kg per min\nEpinephrine: 0\u00b71 \u03bcg/kg per min\nHypoxaemia requiring an increase in the fraction of inspired oxygen of \u22650\u00b72 and increase in positive end-expiratory airway pressure level of 5 cm H2O or more to maintain transcutaneous oxygen saturations in the target range of 88-95%\nNew cardiac arrhythmia requiring cardioversion\nNew ventricular tachycardia, ventricular fi brillation, or asystole\nA clinical scenario consistent with transfusion incompatibility or transfusion-related infection\nCardiac arrest or death within 24 h of mesenchymal stem-cell infusion",
                              "The number of participants with a severe adverse event during the study was assessed.",
                              "Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.",
                              "Days on vasopressor to day 28 after study enrollment",
                              "The number of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.",
                              "The number of patients expired at hospital discharge."
                        ],
                        "OutcomeMeasureDispersionType": [
                              "Full Range",
                              "Full Range",
                              "Full Range"
                        ],
                        "NCTId": [
                              "NCT01775774"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04390152"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT01902082"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT03608592"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04416139"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04289194"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04565665"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04366063"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04602104"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04909879"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04456361"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04625738"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04347967"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT05354141"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT05387278"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT05127122"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT05240430"
                        ]
                  },
                  {
                        "Rank": 19,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04447833"
                        ]
                  },
                  {
                        "Rank": 20,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT02444455"
                        ]
                  },
                  {
                        "Rank": 21,
                        "OutcomeClassDenomCountGroupId": [
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001"
                        ],
                        "OutcomeClassDenomCountValue": [
                              "12",
                              "12",
                              "4",
                              "7",
                              "8",
                              "5",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "3",
                              "3",
                              "3",
                              "2"
                        ],
                        "OutcomeClassDenomUnits": [
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants"
                        ],
                        "OutcomeClassTitle": [
                              "Number of subjects with an increase in vasopressor dose at 6 h",
                              "In subjects receiving mechanical ventilation, Number of subjects with worsening of hypoxemia at 6 h",
                              "In subjects on high flow oxygen therapy:worsening hypoxemia(req intubat, mechanical ventilat) at 6 h",
                              "Number of subjects with new cardiac arrhythmia requiring cardioversion at 6 h",
                              "Number of subjects with new ventricular tachycardia, ventricular fibrillation, or asystole at 6 h",
                              "A clinical scenario consistent with transfusion incompatibility or transfusion-rel infection at 6h",
                              "Number of subjects with cardiac arrest or death within 24 h post infusion",
                              "Number of Adverse Events (not including SAEs)",
                              "Number of Serious Adverse Events",
                              "Mild",
                              "Moderate",
                              "Severe",
                              "Mild",
                              "Moderate",
                              "Severe",
                              "Unrelated",
                              "Unlikely",
                              "Possible",
                              "Probably",
                              "Definite",
                              "Unrelated",
                              "Unlikely",
                              "Possible",
                              "Probable",
                              "Defininte",
                              "Days by which 75% of subjects were recovered",
                              "Days by which 50% of subjects were recovered",
                              "Days by which 25% of subjects were recovered",
                              "PEEP",
                              "Plateau Pressure",
                              "Class I",
                              "Class II",
                              "Class I",
                              "Class II",
                              "Class I",
                              "Class II",
                              "IgM",
                              "IgG"
                        ],
                        "OutcomeDenomCountGroupId": [
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001"
                        ],
                        "OutcomeDenomCountValue": [
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "12",
                              "11",
                              "12",
                              "11",
                              "12",
                              "12",
                              "12",
                              "10",
                              "11",
                              "10",
                              "11",
                              "5",
                              "7",
                              "3",
                              "3",
                              "3",
                              "3",
                              "9",
                              "11",
                              "0",
                              "0",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "8",
                              "9",
                              "8",
                              "9",
                              "9",
                              "9",
                              "5",
                              "6",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "5",
                              "6",
                              "5",
                              "6",
                              "5",
                              "6",
                              "5",
                              "6",
                              "5",
                              "6",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "9",
                              "8",
                              "11",
                              "10",
                              "11",
                              "9",
                              "10",
                              "10",
                              "11",
                              "11",
                              "11",
                              "11",
                              "11",
                              "11",
                              "9",
                              "10",
                              "11",
                              "12",
                              "11",
                              "10",
                              "11",
                              "5",
                              "4",
                              "4",
                              "2"
                        ],
                        "OutcomeDenomUnits": [
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants"
                        ],
                        "OutcomeGroupDescription": [
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol.",
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nUmbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.: UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.\n\nVehicle + Heparin along with best supportive care: Best supportive care treatment per the treating hospital protocol."
                        ],
                        "OutcomeGroupId": [
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001",
                              "OG000",
                              "OG001"
                        ],
                        "OutcomeGroupTitle": [
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group",
                              "UC-MSCs Group",
                              "Control Group"
                        ],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [
                              "Safety as defined by the number of pre-specified infusion associated adverse events as assessed by treating physician. Any of the following occurring within 6 h post each infusion:\n\nAn increase in vasopressor dose greater than or equal to the following:\n\nNorepinephrine: 10 \u03bcg/min\nPhenylephrine: 100 \u03bcg/min\nDopamine: 10 \u03bcg/kg/min\nEpinephrine: 10 \u03bcg/min\nIn patients receiving mechanical ventilation: worsening hypoxemia, as assessed by a requirement for an increase of PEEP by 5 cm H2O over baseline, or requirement to increase FiO2 of >20%.\nIn patients receiving high flow oxygen therapy: worsening hypoxemia, as indicated by requirement of intubation and mechanical ventilation.\nNew cardiac arrhythmia requiring cardioversion\nNew ventricular tachycardia, ventricular fibrillation, or asystole\nA clinical scenario consistent with transfusion incompatibility or transfusion-related infection\nCardiac arrest or death within 24h post infusion",
                              "The number of subjects experiencing serious adverse events by 31 days after the first infusion (corresponding to 28 days after the last infusion).",
                              "Safety will be reported as the percentage of participants experiencing serious adverse events through Day 90 as assessed by treating physician.",
                              "Total number of adverse events and serious adverse events as assessed by treating physician",
                              "Total number of adverse events plus serious adverse events categorized by severity.",
                              "Total number of subjects with adverse events and serious adverse events categorized by severity.",
                              "Total number of adverse events and serious adverse events categorized by relatedness to treatment defined by a medical professional.",
                              "Total number of subjects with adverse events categorized by relatedness to treatment by a medical professional",
                              "Number of participants that are alive at 31 days post first infusion follow up corresponding to 28 day post second infusion.",
                              "Number of participants alive at 60 days post first infusion follow up.",
                              "Time to discharge or, if the subject was hospitalized, no longer requiring supplemental oxygen and no longer requiring COVID-19-related medical care by 31 days. The numbers represent days at which 25%, 50%, 75% subjects within the treatment group had recovered.",
                              "Number of days participants were off ventilators during 28 days post second infusion.",
                              "Number of days participants were off ventilators within up to 90 days of hospitalization.",
                              "Respiratory Rate-Oxygenation (ROX) index is defined as the ratio of oxygen saturation as measured by pulse oximetry (SpO2)/ Fraction of inspired oxygen (FiO2) to respiratory rate. This index can be used in the assessment of disease progression and the risk of intubation in COVID-19 patients with pneumonia.",
                              "Measure of the fraction of inspired oxygen (FiO2) and its usage within the body during intensive care, measured using fNIRS (Functional Near Infrared Spectroscopy). The calculation for Oxygenation index is ((FIO2 * Mean airway pressure)/partial pressure of oxygen).",
                              "Measuring the respiratory mechanics; positive end-expiratory pressure (PEEP) and plateau pressure (Pplat) in ventilated patients visit 8 (day 6)",
                              "Sequential Organ Failure Assessment (SOFA) Scores is used to track a person's risk status during stay in the Intensive Care Unit (ICU). The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each organ system is assigned a point value from a minimum of 0 (normal) to a maximum of 4 (high degree of dysfunction/failure). The total score corresponds to the sum of the six different scores of the organ systems. In total, the minimum SOFA score is 0 (normal) and the maximum SOFA score is 24 (highest degree dysfunction/failure).",
                              "SIT measures the participant's sense of smell. SIT has a total score ranging from 0 to 40 with the higher the score indicating a more normal sense of smell",
                              "As assessed via serum blood samples.",
                              "As assessed via serum blood samples.",
                              "Measures the total amount of the oxygen-carrying protein in the blood as assessed via serum blood samples.",
                              "The percentage by volume of red cells in your blood as assessed via serum blood samples.",
                              "the amount of immune cells (that is one of the first cell types to travel to the site of an infection) as assessed via serum blood samples",
                              "Lymphocyte count as assessed via serum blood samples",
                              "Glomerular filtration rate (GFR) as assessed via serum blood samples to check how well the kidneys are working. It estimates how much blood passes through the glomeruli each minute.",
                              "Total protein as assessed via serum blood samples as a part of the comprehensive metabolic panel (CMP). It is a measurement of the sum of albumin and globulins.",
                              "Sodium levels as assessed by serum blood samples.",
                              "Potassium levels as assessed via serum blood samples.",
                              "Creatinine levels as assessed via serum blood samples",
                              "Glucose levels as assessed via serum blood samples",
                              "Albumin levels as assessed via serum blood samples",
                              "Alkaline phosphatase levels as assessed via serum blood samples for the Comprehensive Metabolic Panel.",
                              "The alanine aminotransferase or serum glutamate-pyruvate transaminase (ALT or SGPT) test as assessed via serum blood samples",
                              "The aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST or SGOT) test as assessed via serum blood samples",
                              "Bilirubin levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Blood urea nitrogen (BUN) levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Calcium levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Chloride levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "Carbon Dioxide (CO2) levels as assessed via serum blood samples for the comprehensive metabolic panel.",
                              "As assessed via serum blood samples.",
                              "As assessed via serum blood samples on day 6 (visit 8).",
                              "As assessed via serum blood samples.",
                              "As assessed via serum blood samples.",
                              "Analysis of TNF\u03b1 in peripheral blood plasma",
                              "Analysis of TNF\u03b2 in peripheral blood plasma",
                              "Analysis of soluble tumor necrosis factor receptor 2 (sTNFR2) in peripheral blood plasma",
                              "Viral load as assessed in blood plasma for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) via Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).",
                              "Number of participants reporting panel reactive antibody (PRA) positivity at Day 3 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
                              "Number of participants reporting panel reactive antibody (PRA) positivity at Day 6 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
                              "Number of participants reporting panel reactive antibody (PRA) positivity at Day 14 post first infusion for class I and class II as assessed via serum blood samples. These antibodies can develop following a transplant. Recipients can become sensitized to certain molecules (Human Leukocyte Antigen Class I or Class II), which can affect immune responses to and rejection of potential future transplants.",
                              "Number of participants with positive, negative, or borderline SARS-CoV-2 Immunoglobulin M (IgM)/Immunoglobulin G (IgG) serology from serum blood samples."
                        ],
                        "OutcomeMeasureDispersionType": [
                              "95% Confidence Interval",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Standard Deviation",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Standard Deviation",
                              "Inter-Quartile Range"
                        ],
                        "NCTId": [
                              "NCT04355728"
                        ]
                  },
                  {
                        "Rank": 22,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04798716"
                        ]
                  },
                  {
                        "Rank": 23,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT03042143"
                        ]
                  },
                  {
                        "Rank": 24,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04905836"
                        ]
                  },
                  {
                        "Rank": 25,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT02112500"
                        ]
                  },
                  {
                        "Rank": 26,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04452097"
                        ]
                  },
                  {
                        "Rank": 27,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04377334"
                        ]
                  },
                  {
                        "Rank": 28,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04390139"
                        ]
                  },
                  {
                        "Rank": 29,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04951882"
                        ]
                  },
                  {
                        "Rank": 30,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04493242"
                        ]
                  },
                  {
                        "Rank": 31,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04629105"
                        ]
                  },
                  {
                        "Rank": 32,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT05491681"
                        ]
                  },
                  {
                        "Rank": 33,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04903327"
                        ]
                  },
                  {
                        "Rank": 34,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04524962"
                        ]
                  },
                  {
                        "Rank": 35,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04728698"
                        ]
                  },
                  {
                        "Rank": 36,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04490486"
                        ]
                  },
                  {
                        "Rank": 37,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04713878"
                        ]
                  },
                  {
                        "Rank": 38,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04657458"
                        ]
                  },
                  {
                        "Rank": 39,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04371393"
                        ]
                  },
                  {
                        "Rank": 40,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04461925"
                        ]
                  },
                  {
                        "Rank": 41,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04333368"
                        ]
                  },
                  {
                        "Rank": 42,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04348461"
                        ]
                  },
                  {
                        "Rank": 43,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04345601"
                        ]
                  },
                  {
                        "Rank": 44,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04494386"
                        ]
                  },
                  {
                        "Rank": 45,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04371601"
                        ]
                  },
                  {
                        "Rank": 46,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04537351"
                        ]
                  },
                  {
                        "Rank": 47,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT02985346"
                        ]
                  },
                  {
                        "Rank": 48,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT05092724"
                        ]
                  },
                  {
                        "Rank": 49,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04400032"
                        ]
                  },
                  {
                        "Rank": 50,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04018729"
                        ]
                  },
                  {
                        "Rank": 51,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04466098"
                        ]
                  },
                  {
                        "Rank": 52,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT01686139"
                        ]
                  },
                  {
                        "Rank": 53,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04602442"
                        ]
                  },
                  {
                        "Rank": 54,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [
                              "Number of participants with serious adverse events during trial",
                              "Number of participants with non-serious adverse events during trial",
                              "Temperature increase",
                              "Bronchospasm",
                              "allergic reaction in the form of swelling Quincke, rash, seizures, etc.",
                              "Other",
                              "Day 1",
                              "Day 2",
                              "Day 3",
                              "Day 4",
                              "Day 5",
                              "Day 6",
                              "Day 7",
                              "Day 8",
                              "Day 9",
                              "Day 10",
                              "Day 1",
                              "Day 11",
                              "at Day 1",
                              "at Day 11"
                        ],
                        "OutcomeDenomCountGroupId": [
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002"
                        ],
                        "OutcomeDenomCountValue": [
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10",
                              "10"
                        ],
                        "OutcomeDenomUnits": [
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants"
                        ],
                        "OutcomeGroupDescription": [
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the first type.\n\nEXO 1 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the second type.\n\nEXO 2 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.",
                              "Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.\n\nPlacebo inhalation: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the first type.\n\nEXO 1 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the second type.\n\nEXO 2 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.",
                              "Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.\n\nPlacebo inhalation: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the first type.\n\nEXO 1 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the second type.\n\nEXO 2 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.",
                              "Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.\n\nPlacebo inhalation: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the first type.\n\nEXO 1 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the second type.\n\nEXO 2 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.",
                              "Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.\n\nPlacebo inhalation: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the first type.\n\nEXO 1 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the second type.\n\nEXO 2 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.",
                              "Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.\n\nPlacebo inhalation: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the first type.\n\nEXO 1 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.",
                              "Participants (n=10) in this group will receive standard therapy and exosomes of the second type.\n\nEXO 2 inhalation: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.",
                              "Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.\n\nPlacebo inhalation: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes)."
                        ],
                        "OutcomeGroupId": [
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002",
                              "OG000",
                              "OG001",
                              "OG002"
                        ],
                        "OutcomeGroupTitle": [
                              "EXO-1",
                              "EXO-2",
                              "Placebo",
                              "EXO-1",
                              "EXO-2",
                              "Placebo",
                              "EXO-1",
                              "EXO-2",
                              "Placebo",
                              "EXO-1",
                              "EXO-2",
                              "Placebo",
                              "EXO-1",
                              "EXO-2",
                              "Placebo",
                              "EXO-1",
                              "EXO-2",
                              "Placebo"
                        ],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [
                              "Safety assessment such as adverse events will be registered. Adverse events will be monitored during all trial",
                              "Safety assessments such as adverse events during the inhalation procedures will be registered.",
                              "Measure and compare time to clinical recovery compared to placebo. Time to clinical recovery calculated by the number of days the patient has hospitalized.",
                              "The concentration of SpO2 by Pulse oximetry device during procedures in the groups. The measure was done before and after each inhalation (total 4 measures per day). The intraday SpO2 data of all patients in groups was calculated as Median with Inter-Quartile Range and presented in the table by days.",
                              "Blood biochemistry C reactive protein level in serum.",
                              "Lactic Acid Dehydrogenase (LDH) level in serum"
                        ],
                        "OutcomeMeasureDispersionType": [
                              "Standard Deviation",
                              "Inter-Quartile Range",
                              "Full Range",
                              "Full Range"
                        ],
                        "NCTId": [
                              "NCT04491240"
                        ]
                  },
                  {
                        "Rank": 55,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04341610"
                        ]
                  },
                  {
                        "Rank": 56,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [],
                        "OutcomeDenomCountGroupId": [],
                        "OutcomeDenomCountValue": [],
                        "OutcomeDenomUnits": [],
                        "OutcomeGroupDescription": [],
                        "OutcomeGroupId": [],
                        "OutcomeGroupTitle": [],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [],
                        "OutcomeMeasureDispersionType": [],
                        "NCTId": [
                              "NCT04399889"
                        ]
                  }
            ]
      }
}